Skip to main content

Table 3 Marginal effects of NI-T2D and coexisting diseases on the HRQoL of respondents as measured with the EQ-5D-5 L and EQ-5D-3 L crosswalk values

From: Impact of type 2 diabetes treated with non-insulin medication and number of diabetes-coexisting diseases on EQ-5D-5 L index scores in the Finnish population

Non-diabetics without coexisting diseases as reference group

Difference in quality of life compared to non-diabetic persons with no coexisting diseases

 

Category, number of coexisting diseases

EQ-5D-5 L index score (95% CI)

EQ-5D-3 L crosswalk index score (95% CI)

No T2D, 0

0 (reference)

0 (reference)

No T2D, 1

−0.053 (−0.061 to −0.046)

−0.079 (−0.089 to −0.069)

No T2D, 2

−0.091 (− 0.103 to − 0.079)

− 0.121 (− 0.135 to − 0.107)

No T2D, 3

− 0.100 (− 0.116 to − 0.083)

−0.136 (− 0.155 to − 0.118)

No T2D, 4 ≥

−0.196 (− 0.235 to − 0.157)

−0.227 (− 0.261 to − 0.193)

NI-T2D, 0

−0.015 (− 0.051 to 0.020)

−0.021 (− 0.073 to 0.031)

NI-T2D, 1

− 0.060 (− 0.084 to − 0.036)

−0.083 (− 0.113 to − 0.053)

NI-T2D, 2

−0.063 (− 0.084 to − 0.041)

−0.086 (− 0.112 to − 0.060)

NI-T2D, 3

−0.097 (− 0.122 to − 0.073)

−0.133 (− 0.160 to − 0.106)

NI-T2D, 4 ≥

−0.222 (− 0.279 to − 0.164)

−0.247 (− 0.296 to − 0.199)

All non-diabetics together as reference group

Difference in quality of life compared to non-diabetic persons

 

Number of coexisting diseases

EQ-5D-5 L index score (95% CI)

EQ-5D-3 L crosswalk index score (95% CI)

No T2D

0 (reference)

0 (reference)

NI-T2D, 0

0.028 (−0.006 to 0.062)

0.039 (−0.012 to 0.090)

NI-T2D, 1

−0.014 (− 0.038 to 0.009)

−0.020 (− 0.049 to 0.010)

NI-T2D, 2

− 0.013 (− 0.033 to 0.007)

−0.019 (− 0.044 to 0.007)

NI-T2D, 3

− 0.043 (− 0.066 to − 0.019)

−0.064 (− 0.091 to − 0.036)

NI-T2D, ≥4

−0.152 (− 0.207 to − 0.097)

−0.170 (− 0.219 to − 0.121)

  1. Results were adjusted for age, sex, income, education, marital status, survey type and employment